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Abstract
Background: In the United States, cisgender men who have sex with men (MSM) who use 
methamphetamine are at substantial risk of HIV and can benefit from pre-exposure prophylaxis 
(PrEP).
Methods: We used data from the National HIV Behavioral Surveillance (NHBS) 2017 survey 
from Seattle, WA; Portland, OR; and Denver, CO to estimate PrEP awareness and use in the past 
12 months among MSM who use methamphetamine. We then compared these estimates to 
participants who do not use methamphetamine but meet other criteria for PrEP use (i.e., 
condomless anal sex or a bacterial sexually transmitted infection). We explored reasons for not 
using PrEP and challenges using PrEP.
Results: Of the 1,602 MSM who participated in the 2017 NHBS survey in Seattle, WA; Portland, 
OR; and Denver, CO, 881 met inclusion criteria for this study, of whom 88 (10%) reported 
methamphetamine use in the past 12 months. Most (95%) participants had heard of PrEP, and 35% 
had used it in the past 12 months. PrEP awareness was lower among MSM who used 
methamphetamine (p=.01), but use was not different (p=.26). Among those who had not used 
PrEP, the most common reason for not using it was not thinking one’s HIV risk was high enough 
(50%). MSM who used methamphetamine were more likely to report that they were not sure PrEP 
would prevent them from getting HIV (38% vs 19%, p=.002).
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Conclusions: These results highlight the need for continued efforts to educate and promote 
PrEP uptake among MSM, particularly those who use methamphetamine.
SUMMARY
Survey results from three cities showed only 35% of PrEP-eligible cismen who have sex with men 
had used PrEP. Awareness and belief in PrEP efficacy were lower among methamphetamine users.
Keywords
HIV prevention; pre-exposure prophylaxis; methamphetamine; National HIV Behavioral 
Surveillance (NHBS)
INTRODUCTION
Daily, oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate 
is a highly effective strategy for preventing HIV that was approved by the U.S. Food and 
Drug Administration in 2012.(1, 2) PrEP is most effective at the population level when used 
by those at elevated HIV risk.(3) In the U.S., cisgender men who have sex with men (MSM) 
have the highest number of new HIV diagnoses, (4) and methamphetamine use among MSM 
is associated with HIV risk behaviors (5, 6) and incidence. (7)
Despite elevated risk for HIV, MSM who use methamphetamine have had limited PrEP 
uptake. In a survey we conducted in 2016 of 221 MSM in Seattle, WA who used 
methamphetamine, 96% had heard of PrEP, but only 3% had used it. (8) The present study 
builds on this work by estimating PrEP awareness and use in a different sample of MSM in 
Seattle, WA and two other cities where MSM are disproportionately impacted by HIV 
infection (9) and methamphetamine use is prevalent. (10) Our hypothesis was that PrEP 
awareness and use would be lower among respondents who use methamphetamine based on 
our previous work.
We used data from the National HIV Behavioral Surveillance (NHBS) 2017 survey (9) from 
Seattle, WA; Portland, OR; and Denver, CO to estimate PrEP awareness and use in the past 
12 months among MSM who use methamphetamine and compared it to estimates among 
participants who do not use methamphetamine. We explored reasons for not using PrEP 
among respondents who had not used it in the past 12 months, as well as challenges using 
PrEP among those who had used it in the past 12 months. Estimating PrEP use among MSM 
who use methamphetamine and understanding reasons for not using PrEP can inform efforts 
to increase PrEP use among persons at high risk for HIV acquisition.
MATERIALS AND METHODS
Data Source
The data included in this analysis were collected between June and December 2017 during 
the 5th NHBS-MSM cycle (9) in Seattle, WA; Portland, OR; and Denver, CO using a cross-
sectional, in-depth behavioral survey. Participants were recruited using venue-based time-
space sampling informed by a formative research phase that identified venues and times to 
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best recruit MSM. (11) Eligibility criteria for the NHBS-MSM survey included self-reported 
age 18 years or older, cisgender male identity, residence within the designated project area, 
ability to complete the survey in English or Spanish, and reporting ever having oral or anal 
sex with a man. All survey participants provided verbal consent and were offered optional 
HIV testing. The survey was administered verbally and was anonymous. Participants were 
provided a $25 (Denver, CO) or $50 (Seattle, WA and Portland, OR) incentive for the survey 
and $25 for the HIV test.
In Seattle, WA and Portland, OR, NHBS has been designated as a surveillance activity and 
data collection activities are not subject to further institutional review board (IRB) review. In 
Denver, CO, NHBS activities are designated as research, and all activities were approved by 
the Colorado Multiple IRB (protocol # 11–0047). The University of Washington Human 
Subjects Division determined that secondary analyses presented here were not human 
subjects research and did not require review.
Study Sample
We used PrEP eligibility criteria adapted from CDC practice guidelines to create a study 
sample eligible for PrEP (Figure 1).(12) First, we restricted our analysis to NHBS 
participants who reported three of the adapted CDC PrEP criteria: never tested positive for 
HIV, had ≥1 male sex partner in the past 12 months, and not in a monogamous relationship 
with an HIV-negative man. Participants who met these criteria were divided into two groups: 
those who had used methamphetamine in the past 12 months [consistent with local PrEP 
eligibility criteria (13)] and a control group who had not used methamphetamine but 
reported other PrEP eligibility criteria (i.e., condomless anal sex (CAS) with a man or 
diagnosis of a bacterial sexually transmitted infection (STI) in the past 12 months).
Measurements
The NHBS survey included a core survey that was identical across sites and a local 
questionnaire customized by each site. We used data from core survey questions that asked 
about demographics, sexual behavior, drug use, HIV testing experiences, and HIV 
prevention activities including PrEP. We added four questions to three local surveys that 
assessed reasons for not using PrEP and challenges using PrEP.
Demographic Characteristics—Demographic characteristics included NHBS site, age 
(continuous), sexual identity (Heterosexual or “Straight,” Homosexual or Gay, or Bisexual), 
race (American Indian or Alaskan Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, or Multiracial), ethnicity (Hispanic or non-
Hispanic), highest level of education (less than high school, high school or equivalent, some 
college, bachelors, post-graduate), homelessness [defined as “living on the street, in a 
shelter, in a Single Room Occupancy hotel (SRO), or in a car” in the past 12 months (yes, 
no)], and health insurance (insured or not).
Sexual Behavior—Questions about sexual behavior in the last 12 months defined the 
study sample. All participants in the sample reported ≥1 male sex partner. We excluded 
participants in a monogamous relationship with an HIV-negative man. Since participants 
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were not explicitly asked if they were in a monogamous relationship, we used answers to 
two separate questions to define this criterion: reporting anal sex with only one HIV-negative 
male partner and that their partner “definitely did not” have sex with other people. We also 
calculated the total number of male CAS partners across four questions that assessed CAS 
with main and casual partners.
Health Conditions—We excluded people who had previously received a positive HIV test 
result. Participants were asked “in the past 12 months, has a doctor or other health care 
provider told you that you had (gonorrhea/chlamydia/syphilis).” Each STI was assessed in a 
separate yes/no question.
Methamphetamine Use—Three core survey questions asked about methamphetamine 
use. Participants were asked about frequency of non-injection methamphetamine use in the 
past 12 months (“never,” “once a week or less,” “more than once a week,” “once a day,” and 
“more than once a day”). Additionally, people who reported injecting drugs in the past 12 
months were asked which drug they injected most often and which other drugs they injected. 
Participants were included in the methamphetamine group if they reported non-injection 
methamphetamine (i.e., any response other than “never”) or injecting methamphetamine in 
the past 12 months.
PrEP Measurements—We used data collected across eight survey questions about PrEP, 
including if participants had ever heard of PrEP and, among those who had, if they had a 
discussion with a health care provider about taking PrEP or had used PrEP in the past 12 
months. Participants who had used PrEP were asked what challenges they experienced using 
it and those who had not taken PrEP were asked reasons for not using PrEP. Participants 
who had used methamphetamine were provided two additional answer options: “PrEP would 
not be safe to use while I am using meth” and “I think meth might make PrEP not work as 
well.” These answer options were informed by our formative work (8). Some participants 
were inadvertently asked the incorrect question about reasons for not using PrEP or asked 
both with the correct question asked second; in these cases the responses to the 
methamphetamine-specific question were considered missing.
Statistical Analysis
PrEP Cascade—We assessed differences in covariates and the proportions who had heard 
of PrEP, discussed it with a provider in the past 12 months, or used it in the past 12 months 
across participants who had used methamphetamine compared to those who had not using 
chi-square tests for categorical variables (with Fisher’s exact tests for expected cell 
frequencies of <5) and Kruskal-Wallis tests for continuous variables. We then used a 
multivariable regression model with a log link and Poisson distribution to assess the 
association between methamphetamine use and PrEP use in the past 12 months after 
adjusting for potential confounders. We adjusted for project site, age, ethnicity, sexual 
identity, highest level of education, and homelessness in the prior year. These covariates 
were chosen a priori based on associations with methamphetamine use (14, 15) and PrEP 
awareness and uptake in other settings. (16–18) Because the proportion of participants who 
had any CAS with a man in the past 12 months was significantly different across groups 
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defined by methamphetamine use, we performed a second, post-hoc, multivariable 
regression that included any male CAS partners in the past 12 months compared to none.
Reasons for not using, and challenges to using, PrEP—We compared the 
frequencies of reasons participants had not used PrEP in the past 12 months and challenges 
using PrEP across groups defined by any methamphetamine use using chi-square tests.
All statistical analysis were conducted in Stata Version 12 (StataCorp, College Station, TX). 
Significance was defined as a p-value <.05.
RESULTS
Of the 1,602 MSM who participated in the 2017 NHBS survey in Seattle, WA; Portland, 
OR; and Denver, CO, 1,135 (71%) were HIV-negative men who reported not being in a 
monogamous relationship with an HIV-negative man and oral or anal sex with a male 
partner in the past 12 months. Among these 1,135 participants, we excluded 254 participants 
who did not report methamphetamine use, a bacterial STI, or CAS in the past 12 months. Of 
the remaining 881 participants, 88 (10%) reported methamphetamine use in the past 12 
months. Of the 793 who did not report methamphetamine use, 770 (97%) reported CAI and 
187 (24%) reported a bacterial STI in the past 12 months.
The demographic characteristics are shown in Table 1. A greater proportion of participants 
who reported methamphetamine use were from Seattle, WA; (49%) than Denver, CO; (28%) 
or Portland, OR (23%) (p=.007). Sexual identity was significantly different across groups 
(p<.001), with more participants who used methamphetamine reporting bisexual identity 
(22% vs 15%) or heterosexual/“straight” identity (6% vs 0%). A smaller proportion of 
participants who used methamphetamine were Hispanic/Latinx (9% vs 21%, p=.008). 
Participants who reported methamphetamine use had fewer years of education (p<.001) and 
were more likely to report homelessness during the past 12 moths (35% vs 4%, p<.001).
Of 88 participants who used methamphetamine, 24 (27%) injected it in the past 12 months, 
and, of those, three participants reported using methamphetamine only via injection. Of the 
85 (97%) who reported using methamphetamine through non-injection methods, six (7%) 
used it more than once a day, five (6%) used it once a day, eight (9%) used it more than once 
a week, and 66 (78%) used it once a week or less.
PrEP Awareness and Use
Nearly all participants had heard of PrEP (833, 95%), most had discussed it with a medical 
provider in the past 12 months (480, 54%), and about one-third of participants had used 
PrEP in the past 12 months (308, 35%). Fewer participants who had used methamphetamine 
had heard of PrEP (89% versus 95% among participants who had not used 
methamphetamine, p=.01). However there were no significant differences comparing 
proportions of participants who had discussed PrEP with a healthcare provider (47% vs 
55%, p=.12) or used PrEP in the past 12 months (30% vs 36%, p=.26). (Figure 2) In 
multivariable analysis, methamphetamine use was not significantly associated with PrEP use 
in the past 12 months, with an adjusted prevalence ratio of 1.07 (95% CI: 0.70–1.65, p=.74). 
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In the post hoc multivariate regression that included any CAS with a male partner in the past 
12 months, there was also no differential PrEP use across groups (APR: 1.10, 95% CI: 0.72–
1.70, p=.65).
Reasons for Not Using PrEP
Table 2 shows reasons participants were not using PrEP among those who had heard of 
PrEP, by group. The most common reason for not using PrEP was “I don’t think my risk for 
HIV is high enough to be on PrEP” (54% among participants who had used 
methamphetamine and 51% among those who had not, p=.68). The second most common 
reason among both groups was “I worry about the side effects” (42% versus 48%, p=.40). 
Among participants who used methamphetamine, the third most common reason was “I am 
not sure it would prevent me from getting HIV” (38%). Being unsure of PrEP’s effectiveness 
was reported by a significantly higher proportion of participants who had used 
methamphetamine (38% vs. 19%, p=.002).
Among the 24 participants who had used methamphetamine in the past 12 months and were 
asked the reasons they had not used PrEP specific to methamphetamine use, three (13%) 
said “PrEP would not be safe to uses while I am using meth” and six (25%) said “I think 
meth might make PrEP not work as well.”
Challenges Using PrEP
Among the 308 participants who had taken PrEP in the past 12 months there was no 
significant difference in challenges taking PrEP comparing those who had used 
methamphetamine (26, 8%) and those who had not used methamphetamine (282, 92%) in 
the past 12 months (Table 3). The most common responses were not experiencing any 
challenges (31% among participants who had used methamphetamine and 29% among those 
who had not, p=.83) and that “it is hard to remember to take a pill every day” (31% versus 
23%, p=.38).
DISCUSSION
MSM who use methamphetamine are disproportionately impacted by HIV in western U.S. 
cities and should be a priority population for PrEP. In this analysis of the 2017 NHBS MSM 
survey from Seattle, WA; Portland, OR; and Denver, CO, we found that while nearly all 
PrEP-eligible MSM had heard of PrEP, significantly fewer MSM who used 
methamphetamine had heard of it. In addition, not believing that PrEP would be effective in 
preventing HIV was reported by a significantly larger proportion of respondents who used 
methamphetamine. Increasing PrEP awareness among MSM who use methamphetamine as 
well as providing accurate information about PrEP’s effectiveness is needed. In an earlier 
PrEP educational intervention we developed targeted to MSM who use methamphetamine in 
Seattle, WA, we found that there was a trend between seeing local educational materials and 
PrEP use,(8) indicating that, in addition to increasing PrEP awareness, targeted educational 
materials may also impact uptake among MSM who use methamphetamine.
Consistent with findings in other PrEP continuums among MSM,(19, 20) only a portion of 
those who had heard of PrEP had discussed it with a health care provider in the past 12 
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months, and even fewer had used it. The decreases across the PrEP continuum, which were 
slightly steeper among MSM who used methamphetamine, highlight the need for increasing 
provider discussions about PrEP to improve PrEP uptake. The majority of the sample who 
had not used PrEP reported they were not using it because they did not think their risk for 
HIV is high enough even though everyone in the sample met eligibility for PrEP. Low risk 
perception has been a barrier in other settings where MSM meet criteria for PrEP use.(21–
23) Approximately one-third of our sample had used PrEP in the past 12 months, which was 
similar to the prevalence of PrEP use in the national NHBS survey sample and is an increase 
since 2014.(24) However, considering that everyone in this sample met PrEP eligibility 
criteria, only one-third reporting past-year use highlights gaps in PrEP provision.
The similar proportion of PrEP use in the past 12 months that we found among those who 
had used methamphetamine and those who had not was inconsistent with prior data among 
MSM in Seattle, WA (8) and our hypothesis that methamphetamine use would be a barrier to 
PrEP uptake. We think that this may be due to two factors: first, PrEP use has been 
increasing in the U.S.,(24) and it is possible that MSM who use methamphetamine have had 
increased uptake as PrEP has become more available. Alternatively, it is possible that this 
sample does not include a substantial number of MSM who use methamphetamine who are 
at the highest risk of HIV acquisition.
In formative work we did among MSM who use methamphetamine in Seattle, WA, which 
was recruited by needle exchange peer educators, 85% reported using methamphetamine at 
least weekly, and only 3% reported using PrEP.(8) In the present analysis, only 22% of 
respondents who had used methamphetamine in the past 12 months used it weekly or more 
frequently and the remaining 78% may have used it only once in the prior year. Furthermore, 
less than one-third (27%) had injected methamphetamine in the past 12 months, which is a 
subgroup of MSM who use methamphetamine at even higher risk for HIV.(25) The 
frequency of methamphetamine use in the present study may impact the generalizability of 
findings across the broader population of MSM who use methamphetamine in Seattle, WA; 
Portland, OR; and Denver, CO. Moreover, since the frequency of methamphetamine use is 
not commonly collected in studies, associations between the frequency of use and HIV risk 
are understudied. While all MSM who use methamphetamine should be a focus of PrEP 
efforts, MSM who inject methamphetamine or are living homeless may be particularly 
vulnerable and require additional, unique outreach methods. This could include 
collaborating with organizations who already provide services to these groups (e.g., syringe 
services programs) or recruiting participants from certain venues where MSM who use 
methamphetamine may be more likely to be at higher risk for HIV (e.g., bathhouses).
This study has several limitations. First, all data are self-reported and may be impacted by 
recall or social desirability bias, especially considering questions were related to sensitive 
and illegal behaviors. However, the survey was administered anonymously by trained 
interviewers, which should have helped mitigate the effects of social desirability bias. 
Second, because we asked about PrEP use in the last 12 months and not current use or 
discontinuations, we could not measure if participants had persisted using PrEP and if 
persistence was lower among those who used methamphetamine, which has been seen in 
other settings.(26) Third, in some of our analyses, sample sizes were small, limiting 
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multivariable analyses. This included only a subset of the participants (n=24) who used 
methamphetamine being asked the question about reasons they had not used PrEP that had 
methamphetamine-specific barriers. While we were unable to assess these 
methamphetamine-specific barriers across the whole sample of participants who used 
methamphetamine but had not used PrEP, these 24 participants were not significantly 
different from other participants who used methamphetamine, with the exception of study 
site, since the administrative error was site-specific. We did, however, collect detailed 
information regarding reasons PrEP-eligible MSM were not using PrEP and challenges 
using it among a large sample of MSM. Finally, these results may not be generalizable 
outside of this sample, especially among groups that may report higher risk for HIV or more 
frequent methamphetamine use or use other substances. Our findings also may not reflect 
MSM in other geographic locations; however, methamphetamine use is less prevalent among 
MSM in other parts of the U.S.(27) Future research should measure PrEP awareness and use 
among different subgroups of people who use methamphetamine that may be at higher risk 
for HIV, including transgender persons, (28) persons living homeless, sex workers, and 
MSM who inject drugs.(25, 29, 30)
CONCLUSIONS
In conclusion, we found that participants who used methamphetamine had significantly 
lower PrEP awareness and belief in PrEP effectiveness. Participants who had not used PrEP 
but met eligibility criteria reported low HIV risk as their primary reason they had not used 
PrEP. While there was no significant difference of PrEP use in the past 12 months 
comparing participants who had used methamphetamine to those who had not, only about 
one-third of MSM meeting PrEP eligibility criteria had used it in the past 12 months. Our 
research highlights the need to educate and promote PrEP uptake among MSM who are at 
elevated risk for HIV, including those who use methamphetamine. Efforts to increase PrEP 
uptake could include offering PrEP at locations or by organizations that already engage 
MSM who use methamphetamine.
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Figure 1. 
Flowchart of the Analytical Selection Process Using Adapted CDC PrEP Criteria Among 
NHBS 2017 MSM Survey Respondents in Seattle, WA; Portland, OR; and Denver, CO
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Figure 2. 
PrEP Awareness, Discussions with Providers in Past 12 Months, and Use in Past 12 Months 
Among NHBS 2017 MSM Survey Respondents in Seattle, WA; Portland, OR; and Denver, 
CO Who Met Adapted CDC PrEP Eligibility Criteria, by Methamphetamine Use in Past 12 
Months (n=881)
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Table 1.
Demographic Characteristics Comparing NHBS 2017 MSM Survey Respondents in Seattle, WA; Portland, 
OR; and Denver, CO Who Met Adapted CDC PrEP Eligibility Criteria by Past 12 Months Methamphetamine 
Use (N=881)
CharacteristicsƗ Methamphetamine Use in Past Year (n=88)
No Methamphetamine Use in Past 
Year (n=793)
P-value
n (%) n (%)
Site
Denver 25 28% 299 38% .007
Portland 20 23% 240 30%
Seattle 43 49% 254 32%
Age (median, IQR) 32 (28–38) 32 (26–41) .91
Sexual identity <.001
Heterosexual or “straight” 5 6% 2 0%
Homosexual or Gay 64 73% 670 84%
Bisexual 19 22% 119 15%
Race .50
American Indian or Alaska Native 1 1% 24 3%
Asian 1 1% 28 4%
Black or African-American 6 7% 51 6%
Native Hawaiian or Other Pacific Islander 1 1% 7 1%
White 61 69% 584 74%
Multiracial 13 15% 80 10%
Ethnicity .008
Not Hispanic/Latinx 79 90% 625 79%
Hispanic/Latinx 8 9% 167 21%
Highest Level of Education Completed <.001
< 12 Grade 12 7 8% 5 1%
Grade 12 or GED 25 28% 124 16%
Some college, AA, or Tech 38 43% 254 32%
Bachelors degree 16 18% 261 33%
Any post-grad 2 2% 149 19%
Homeless <.001
Homeless in past year 31 35% 34 4%
Health insurance .044
Currently have health insurance 70 80% 692 87%
Ɨ
There were 2 missing values for sexual identity and ethnicity and 24 missing values for race.
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Table 3.
Challenges Using PrEP Among NHBS 2017 MSM Survey Respondents in Seattle, WA; Portland, OR; and 
Denver, CO Who Met Adapted CDC PrEP Eligibility Criteria and Had Used PrEP in the Past 12 Months, by 
Past Year Methamphetamine Use (n=308)
Challenges Using PrEP Among Participants 
Who Had Used PrEP in the Past 12 Months
Participants Who Had Used 
Methamphetamine in the Past 12 
Months (n=26)
Participants Who Had Not Used 
Methamphetamine in the Past 12 
Months (n=282) p-value
n % n %
I haven’t experienced any challenges taking 
PrEP 8 31% 81 29% .83
It is hard to remember to take a pill every day 8 31% 65 23% .38
Other reason(s) 7 27% 50 18% .25
It is hard to make it to my clinic visits for refills 5 19% 33 12% .26
I lost my insurance/can’t afford it anymore 4 15% 30 11% .51
I have experienced side effects 2 8% 51 18% .28
I don’t think my risk for HIV is high enough to 
be on PrEP 2 8% 27 10% 1.0
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